Log in to search using one of your social media accounts:

 

Aurobindo Pharma gets USFDA nod for HIV drug
"The company has received final approval from the USFDA to manufacture abacavir sulfate and lamivudine tablets, 600 mg/ 300 mg." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 30, 2017 Category: Pharmaceuticals Source Type: news

EPZICOM (Abacavir Sulfate And Lamivudine) Tablet, Film Coated
Updated Date: Mar 21, 2017 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - March 21, 2017 Category: Drugs & Pharmacology Source Type: news

ABACAVIR AND LAMIVUDINE (Abacavir Sulfate And Lamivudine) Tablet, Film Coated [Prasco Laboratories]
Updated Date: Sep 30, 2016 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - September 30, 2016 Category: Drugs & Pharmacology Source Type: news

EPZICOM (Abacavir Sulfate And Lamivudine) Tablet, Film Coated [A-S Medication Solutions]
Updated Date: Sep 6, 2016 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - September 6, 2016 Category: Drugs & Pharmacology Source Type: news

​ Lupin looks to launch 25 products in US this fiscal
In the current year, apart from the Gavis portfolio, Fortamet and Glumetza, the company expects to launch products like Minastrin and Epzicom. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 15, 2016 Category: Pharmaceuticals Source Type: news

EPZICOM (Abacavir Sulfate And Lamivudine) Tablet, Film Coated [A-S Medication Solutions]
Updated Date: May 2, 2016 EST (Source: DailyMed Drug Label Updates)
Source: DailyMed Drug Label Updates - May 2, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Approves New Fixed-Dose Combination Drug, Triumeq (Abacavir Sulfate/Dolutegravir/Lamivudine), to Treat HIV Infection
"On August 22, 2014, FDA approved a new fixed-dose combination product: TRIUMEQ, a combination of dolutegravir (integrase strand transfer inhibitor), abacavir sulfate and lamivudine (both nucleoside analogue reverse transcriptase inhibitors) for the treatment of HIV-1 infection.  "TRIUMEQ alone is not recommended for use in patients with current or past history of resistance to any components of TRIUMEQ. "TRIUMEQ alone is not recommended in patients with resistance-associated integrase substitutions or clinically suspected integrase strand transfer inhibitor resistance because the dose of dolutegra...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 29, 2014 Category: Infectious Diseases Source Type: news

Update on Patent Ruling on ViiV Healthcare's EPZICOM® and TRIZIVIR®
GSK and ViiV Healthcare confirmed today that the US District Court for the District of Delaware upheld the validity of a patent covering the double combination of lamivudine and abacavir (Epzicom®) and the triple combination of lamivudine, abacavir and zidovudine (Trizivir®). (Source: GSK news)
Source: GSK news - December 18, 2013 Category: Pharmaceuticals Source Type: news

Switch From Epzicom to Truvada Maintains HIV Suppression: StudySwitch From Epzicom to Truvada Maintains HIV Suppression: Study
Virologic suppression was maintained when HIV patients switched from lamivudine/abacavir (ABC/3TC) to emtricitibine/tenofovir (FTC/TDF) in the pharma-funded SWIFT study. Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 4, 2013 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news